Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

This is especially true if you meet the medical criteria to use a GLP-1 medication for weight loss – meaning you have a body mass index greater ... spokesperson for Novo Nordisk, the company ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

According to the CDC, frequent consumption of sugary drinks is linked to adverse health outcomes that include obesity, type 2 ...

The glycemic index is a measure used to determine how much a food can affect your blood sugar levels. Several factors affect the glycemic index of a food, including the ripeness, nutrient ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the ... conjunction with diet and exercise to enhance glycemic control in persons with type 2 diabetes.

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...